Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

cGAS-STING signalling in cancer: striking a balance with chromosomal instability.

Beernaert B. and Parkes EE., (2023), Biochem Soc Trans

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.

Fletcher CE. et al, (2022), Mol Cancer, 21

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.

van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.

Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258

The tumor microenvironment and immune responses in prostate cancer patients.

Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107

Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.

Harrington K. et al, (2021), CANCER RESEARCH, 81

The clinical and molecular significance associated with STING signaling in breast cancer.

Parkes EE. et al, (2021), NPJ Breast Cancer, 7

Development of Immunotherapy Combination Strategies in Cancer.

Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.

Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100

The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer

Parkes EE. et al, (2020)

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492

Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study

McCain RS. et al, (2019), Cancer Causes & Control, 31, 1 - 11

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC. et al, (2019), Gut, 68, 1918 - 1927

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy

Gilmore E. et al, (2019), JOURNAL OF ONCOLOGY, 2019

Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application

Lightbody G. et al, (2019), BRIEFINGS IN BIOINFORMATICS, 20, 1795 - 1811

Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation

Wilkinson RDA. et al, (2019)

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199

Load More